Heron Therapeutics (NASDAQ:HRTX) Issues Quarterly Earnings Results

Heron Therapeutics (NASDAQ:HRTX) released its quarterly earnings data on Tuesday. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03), Zacks reports. The company had revenue of $32.81 million during the quarter, compared to analysts’ expectations of $36.40 million. During the same period last year, the firm earned ($0.17) earnings per share. Heron Therapeutics updated its Q4 2024 guidance to EPS and its FY 2024 guidance to EPS.

Heron Therapeutics Trading Down 4.3 %

Shares of NASDAQ HRTX traded down $0.06 during trading hours on Wednesday, hitting $1.23. 2,705,488 shares of the stock were exchanged, compared to its average volume of 2,421,421. The firm has a fifty day moving average price of $1.86 and a 200-day moving average price of $2.54. Heron Therapeutics has a 12 month low of $0.53 and a 12 month high of $3.93.

Analysts Set New Price Targets

Separately, Needham & Company LLC lowered their price objective on shares of Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.